Check out this episode as Dr. Dave Dixon talks about REDUCE-IT and REDUCE-IT USA.
0:00-0:41: Intro
0:42-1:26: Introduction of Dr. Dave Dixon
1:27-5:10: Introduction of REDUCE-IT and REDUCE-IT USA
5:11-6:30: Dave’s Initial Thoughts
6:31-8:21: Why not OTC fish oil or omega-3 fatty acid prescriptions?
8:22-9:54: Were these patients well managed at baseline?
9:55-11:15: Who should we avoid icosapent ethyl in?
11:16-12:19: Labeling Changes
12:20-14:16: Final Thoughts
14:17-15:01: Closing
References:
REDUCE-IT: Bhatt DL, Steg G, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med2019;380:11-22.
REDUCE-IT USA: Bhatt DL, Miller M, BrintonE, et al. REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States. Circulation 2019; doi: 10.1161/CIRCULATIONAHA.119.044440.
FDA New Release: https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups
CardioScripts 